Clinical Trial Update: Intermediate-Size Expanded Access Protocol (EAP) for LP352

View source ↗

Summary

Update on Longboard Pharmaceuticals' expanded access protocol for LP352, indicating availability for patients with Dravet syndrome, Lennox-Gastaut syndrome, and…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Developmental and Epileptic Encephalopathy
• Dravet Syndrome
• Lennox-gastaut Syndrome

Drugs mentioned

• LP352

Snippet

Sponsor: Longboard Pharmaceuticals | Conditions: Dravet Syndrome, Lennox Gastaut Syndrome | Status: AVAILABLE